# Xeris Biopharma Holdings, Inc.: Form 8-K, filed Mar 6, 2024

- Company: [Xeris Biopharma Holdings, Inc.](/companies/xers.md) (CIK 1867096)
- Form: 8-K
- Filed: 2024-03-06
- Accepted by EDGAR: Mar 6, 2024, 07:27 ET
- Period: 2024-03-05
- Accession: 0001867096-24-000024
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000024/xers-20240305.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000024/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 2.02: Results of operations
- Item 2.03: New direct financial obligation
- Item 8.01: Other events

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1867096/000186709624000024/xers-20240305.htm

Filed Mar 6, 2024.
Source: SEC EDGAR, the filing index for accession 0001867096-24-000024. Last ingested by Listed: Nov 6, 2026, 17:33 ET. No prices; not investment advice.
